Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.59 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.46 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371645 | 1.00 | PPARA (0.61) | PPARAPPARGCTSSPTPN1SCN9A | |
| SCHEMBL5001325 | 1.00 | PPARA (0.61) | PPARAPPARGCTSSPTPN1SCN9A | |
| SCHEMBL5007447 | 0.88 | PPARA (0.65) | PPARAPPARGCTSSPTPN1CTSK | |
| SCHEMBL5007452 | 0.88 | PPARA (0.65) | PPARAPPARGCTSSPTPN1CTSK | |
| SCHEMBL1270449 | 0.86 | SCN9A (0.54) | CTSSPTPN1SCN9ACACNA1CCYP3A4 | |
| SCHEMBL1270451 | 0.86 | SCN9A (0.54) | CTSSPTPN1SCN9ACACNA1CCYP3A4 | |
| SCHEMBL5001374 | 0.84 | PPARA (0.64) | PPARAPPARGCTSSPTPN1SCN9A | |
| SCHEMBL5001376 | 0.84 | PPARA (0.64) | PPARAPPARGCTSSPTPN1SCN9A | |
| SCHEMBL5004857 | 0.84 | PPARA (0.66) | PPARAPPARGCTSSPTPN1SCN9A | |
| SCHEMBL5004856 | 0.84 | PPARA (0.66) | PPARAPPARGCTSSPTPN1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102256944-A | Sphingosine-1-phosphate receptor antagonists | EXELIXIS INC | 2011-11-23 | — | — | CN | disclosed |
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050240001-A1 | 2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; endogenous human growth hormone controller; non-peptidyl in nature, more metabolically stable | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1497316-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003087070-A2 | GROWTH HORMONE SECRETAGOGUES | ELI LILLY AND COMPANY (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | PPARA 1880/4885PPARG 2471/4885CTSS 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.